ES2571539T3 - Nuevos compuestos de hexahidropirroloimidazolona - Google Patents

Nuevos compuestos de hexahidropirroloimidazolona

Info

Publication number
ES2571539T3
ES2571539T3 ES12719369T ES12719369T ES2571539T3 ES 2571539 T3 ES2571539 T3 ES 2571539T3 ES 12719369 T ES12719369 T ES 12719369T ES 12719369 T ES12719369 T ES 12719369T ES 2571539 T3 ES2571539 T3 ES 2571539T3
Authority
ES
Spain
Prior art keywords
substituted
heteroaryl
phenyl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES12719369T
Other languages
English (en)
Inventor
Aurelia Conte
Daniel Hunziker
Werner Neidhart
Matthias Nettekoven
Tanja Schulz-Gasch
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Application granted granted Critical
Publication of ES2571539T3 publication Critical patent/ES2571539T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Compuestos de la fórmula (I)**Fórmula** en la que: R1 es alquilo, haloalquilo, alcoxialquilo, haloalcoxialquilo, hidroxialquilo, fenilo, fenilo sustituido, fenilalquilo, fenilalquilo sustituido, fenoxialquilo, fenoxialquilo sustituido, heteroarilo, heteroarilo sustituido, heteroarilalquilo o heteroarilalquilo sustituido, dichos fenilo sustituido, fenilalquilo sustituido, fenoxialquilo sustituido, heteroarilo sustituido y heteroarilalquilo sustituido están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre alquilo, cicloalquilo, cicloalquilalquilo, halógeno, haloalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, haloalcoxi, hidroxihaloalquilo y alcoxihaloalquilo; R2 es fenilo, fenilo sustituido, heteroarilo o heteroarilo sustituido, dichos fenilo sustituido y heteroarilo sustituido están sustituidos de una a tres veces por sustituyentes elegidos con independencia entre alquilo, cicloalquilo, cicloalquilalquilo, halógeno, haloalquilo, hidroxi, hidroxialquilo, alcoxi, alcoxialquilo, haloalcoxi, hidroxihaloalquilo y alcoxihaloalquilo; R3 es hidrógeno, hidroxi o alcoxi, en el caso de que R3 sea hidroxi o alcoxi, entonces A es un enlace; R4 es hidrógeno, alquilo o cicloalquilo; R5 es hidrógeno, alquilo o cicloalquilo; A es -O-, -OC(O)-, -NR4C(O)O-, -NR4-, -C(O)NR4-, -NR4C(O)NR5-, -S(O)2NR4-, -NR4S(O)NR5-, -NR4S(O)2NR5-, -S-, -S(O)-, -S(O)2- o un enlace, en el caso de que A sea un enlace, entonces R1 es alcoxialquilo o haloalcoxialquilo; o las sales farmacéuticamente aceptables de los mismos.
ES12719369T 2011-05-09 2012-05-04 Nuevos compuestos de hexahidropirroloimidazolona Active ES2571539T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11165232 2011-05-09
PCT/EP2012/058173 WO2012152663A1 (en) 2011-05-09 2012-05-04 New hexahydropyrroloimidazolone compounds

Publications (1)

Publication Number Publication Date
ES2571539T3 true ES2571539T3 (es) 2016-05-25

Family

ID=46044696

Family Applications (1)

Application Number Title Priority Date Filing Date
ES12719369T Active ES2571539T3 (es) 2011-05-09 2012-05-04 Nuevos compuestos de hexahidropirroloimidazolona

Country Status (12)

Country Link
US (1) US8497288B2 (es)
EP (1) EP2707371B1 (es)
JP (1) JP6126080B2 (es)
KR (1) KR20140029478A (es)
CN (1) CN103517905B (es)
BR (1) BR112013028945A2 (es)
CA (1) CA2834497A1 (es)
ES (1) ES2571539T3 (es)
HK (1) HK1191946A1 (es)
MX (1) MX344429B (es)
RU (1) RU2013153191A (es)
WO (1) WO2012152663A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112390734A (zh) * 2019-08-15 2021-02-23 中国科学院大连化学物理研究所 磺酰胺衍生物、其药物组合物和应用

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001007052A1 (en) * 1999-07-21 2001-02-01 Boehringer Ingelheim Pharmaceuticals, Inc. Small molecules useful in the treatment of inflammatory disease
TW200303200A (en) * 2002-02-07 2003-09-01 Tanabe Seiyaku Co Inhibitors of α L β 2 integrin mediated cell adhesion
TW200407324A (en) * 2002-05-17 2004-05-16 Bristol Myers Squibb Co Bicyclic modulators of androgen receptor function
JP2005068145A (ja) * 2003-08-06 2005-03-17 Tanabe Seiyaku Co Ltd 医薬組成物
US7696241B2 (en) * 2004-03-04 2010-04-13 Bristol-Myers Squibb Company Bicyclic compounds as modulators of androgen receptor function and method
GB0517966D0 (en) * 2005-09-02 2005-10-12 Novartis Ag Organic compounds
US8124636B2 (en) * 2008-04-30 2012-02-28 Hoffmann-La Roche Inc. Imidazolidinone derivatives as 11B-HSD1 inhibitors
BRPI0914933B1 (pt) 2008-06-30 2018-09-25 Monsanto Technology Llc Polipeptídeo exibindo atividade de aspartato quinase (ak) que não é sujeito a inibição por produto final, polinucleotídeo codificando o mesmo, construto de dna recombinante,microrganismo transformado, produto alimentício, farelo ou farinha, bem como métodos de transformação de uma célula de planta, de produção de uma planta transformada e de aumento do teor de aminoácido livre total de uma planta.
US8673917B2 (en) * 2008-09-09 2014-03-18 Sanofi 2-heteroaryl-pyrrolo [3,4-C]pyrrole derivatives, and use thereof as SCD inhibitors
US8329904B2 (en) 2009-05-12 2012-12-11 Hoffmann-La Roche Inc. Azacyclic derivatives
US8501768B2 (en) * 2011-05-17 2013-08-06 Hoffmann-La Roche Inc. Hexahydrocyclopentapyrrolone, hexahydropyrrolopyrrolone, octahydropyrrolopyridinone and octahydropyridinone compounds

Also Published As

Publication number Publication date
JP6126080B2 (ja) 2017-05-10
EP2707371B1 (en) 2016-04-20
US20120289549A1 (en) 2012-11-15
CN103517905B (zh) 2016-08-24
WO2012152663A1 (en) 2012-11-15
CA2834497A1 (en) 2012-12-15
BR112013028945A2 (pt) 2018-04-10
HK1191946A1 (zh) 2014-08-08
MX2013013021A (es) 2013-12-02
JP2014516949A (ja) 2014-07-17
US8497288B2 (en) 2013-07-30
MX344429B (es) 2016-12-15
EP2707371A1 (en) 2014-03-19
CN103517905A (zh) 2014-01-15
KR20140029478A (ko) 2014-03-10
RU2013153191A (ru) 2015-06-20

Similar Documents

Publication Publication Date Title
AR076435A1 (es) Compuestos de indazoles sustituidos, composiciones farmaceuticas que los contienen y procesos de obtencion de los mismos
CR20120361A (es) Compuestos divalentes y heterocíclicos unidos por puente oxa relacionados con nicotina y métodos de preparación de los mismos
CR20140294A (es) Derivados de dihidro-benzo-oxazina y dihidro-pirido-oxazina
AR090539A1 (es) COMPUESTOS INHIBIDORES DE b LACTAMASA
PE20160044A1 (es) Moduladores de las enzimas modificadoras de los metilos, composiciones que los comprenden y sus usos
AR052568A1 (es) Derivados de pirazolo -pirimidina como antagonstas de mglur2
CR11241A (es) Compuestos de pirazol y su uso como inhibidores de raf
CO7170163A2 (es) Composiciones fungicidas
RS54175B1 (en) BROMODOMEN INHIBITORS AND THEIR APPLICATION
CR20110370A (es) Derivados de sulfonamida
RS54730B1 (sr) Inhibitori beta sekretaze
EA200802380A1 (ru) Совместные кристаллы пирролидинонов
AR085088A1 (es) Inhibidores de histona desacetilasa y composiciones farmaceuticas que los contienen
SV2011003825A (es) Nuevos derivados de acilaminobenzamida
SV2009003199A (es) Nuevos derivados de diosmetina, su procedimiento de preparacion y las composiciones farmaceuticas que los contienen
AR072803A1 (es) Tetrahidrocinolinas como inhibidores de la 11- beta -hsd1 para la diabetes
AR081819A1 (es) Derivados de pirimidil-piperidinil-oxipiridinona, composiciones farmaceuticas que los contienen y uso de los mismos para tratar diabetes, dislipemias, obesidad y otras enfermedades
AR070485A1 (es) Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica
AR085236A1 (es) Compuestos de benzodioxol-piperazina como moduladores de los receptores 5-hty d
AR092173A1 (es) Inhibidores de la syk
AR083861A1 (es) OXAZOLIDINONAS COMO MODULADORES DE mGluR5 Y COMPOSICIONES FARMACEUTICAS QUE LOS CONTIENEN
CO6420339A2 (es) Derivados de 6-(6-sustituido-triazolopiridacina-sulfanil) 5-fluoro-benzotiazoles y 5-fluoro-bencimidazoles : preparación, aplicación como medicamentos y utilización como inhibidores de met
UY33299A (es) Derivados de 6-(alquil-o cicloalquil-triazolopiridacina-silfanil)benzotiazoles:preparacion, aplicación como medicamentos y utilizacion como inhibidores de la met
AR085909A1 (es) Derivados de azaespirodecanona, composiciones farmaceuticas que los contienen, procedimiento para prepararlos y uso de los mismos para el tratamiento de diabetes, obesidad y enfermedades cardiovasculares, entre otras
AR085542A1 (es) Compuestos de azaespirodecanona como inhibidores de hsl